Economic analyses conducted in the era pre-biologic therapy mostly centered upon the estimation or calculation of the direct costs of IBD treatment. Some rough extrapolations of the indirect costs ...

The introduction of biologics has changed treatment for many people with ulcerative colitis. Here’s what you need to know about the risks and benefits. Over the past 15 years, treatment options ...

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling ...

Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

In patients with paediatric-onset inflammatory bowel disease (IBD), a familial history of IBD did not exhibit an increased use of immunomodulators or biologic agents compared with sporadic forms ...

You may feel nervous to try biologics for ulcerative colitis if you haven’t taken them before. However, if other treatments have not worked for you, these medications might be more effective.

Ideal Drug Attributes and Current Gaps In terms of efficacy, an ideal IBD therapy should induce and sustain remission rates exceeding 50–60%. Current biologics and oral treatments typically ...

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

Two years ago, 10-year-old Bo Bratschie experienced weight loss and high fevers, leading to many hospital visits before being diagnosed with Crohn’s disease at ...

biologics, and small molecule therapies are FDA-approved for Crohn’s disease, ulcerative colitis, or both. The location of your disease influences which treatment is right for you; for example ...

Clinical trials of new biologics in patients with inflammatory ... response and/or secondary loss of response to treatment in patients with IBD? Melia: In general, for most of the drugs used ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) for adults with moderately to severely active Crohn’s disease who have not ...